IP Library › Granted Patent US 11,666,763
Granted Patent B2
US 11,666,763 · App. 16/895,402 · Granted Jun 6, 2023

Anti-tachycardia pacing control in an implantable medical device system

Inventors: Xusheng Zhang (Shoreview, MN); Yanina Grinberg (Plymouth, MN); Paul R. Solheim (Blaine, MN); Troy E. Jackson (Rogers, MN); Timothy A. Ebeling (Circle Pines, MN); Vladimir P. Nikolski (Blaine, MN)
Assignee: Medtronic, Inc.
A61N1/3622A61N1/3624A61N1/36507A61N1/37217A61N1/3987A61N1/39622A61N1/3756A61N1/37512A61N1/3918
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,666,763
App. No.
16/895,402
Granted
Jun 6, 2023
Kind
B2
Abstract

An implantable medical device system is configured to detect a tachyarrhythmia from a cardiac electrical signal and start an ATP therapy delay period. The implantable medical device determines whether the cardiac electrical signal received during the ATP therapy delay period satisfies ATP delivery criteria. A therapy delivery module is controlled to cancel the delayed ATP therapy if the ATP delivery criteria are not met and deliver the delayed ATP therapy if the ATP delivery criteria are met.

Claims (69)

1. A medical device comprising:

a sensing circuit configured to receive a cardiac electrical signal;

a control circuit coupled to the sensing circuit and configured to:

detect a tachyarrhythmia from the cardiac electrical signal; and

start an anti-tachycardia pacing (ATP) therapy delay period in response to detecting the tachyarrhythmia; and

a therapy delivery circuit coupled to the control circuit, the therapy delivery circuit comprising a high voltage capacitor chargeable to a shock voltage amplitude for delivering a cardioversion/defibrillation shock pulse; the therapy delivery circuit configured to:

adjust a charge of the high voltage capacitor to a pacing voltage amplitude during the ATP therapy delay period, the pacing voltage amplitude being less than the shock voltage amplitude.

2. The medical device of claim 1 , wherein:

the control circuit is further configured to:

determine the charge of the high voltage capacitor during the ATP therapy delay period; and

determine when the charge of the high voltage capacitor is within a tolerance of the pacing voltage amplitude; and

the therapy delivery circuit is further configured to deliver a delayed ATP therapy after the ATP therapy delay period in response to the high voltage capacitor being within the tolerance of the pacing voltage amplitude during the ATP therapy delay period.

3. The medical device of claim 2 , wherein the therapy delivery circuit is configured to:

cancel the delayed ATP therapy in response to the high voltage capacitor not being within the tolerance of the pacing voltage amplitude during the ATP therapy delay period; and

charge the high voltage capacitor to the shock voltage amplitude in response to the ATP therapy being cancelled.

4. The medical device of claim 1 , wherein:

the control circuit is further configured to determine that ATP delivery criteria are not satisfied based on the cardiac electrical signal received by the sensing circuit during the ATP therapy delay period; and

the therapy delivery circuit is further configured to cancel a delayed ATP therapy in response to the ATP delivery criteria not being satisfied.

5. The medical device of claim 1 , wherein:

the control circuit is further configured to determine that a cardiac event sensed by the sensing circuit from the cardiac electrical signal during the ATP therapy delay period is a slowing event; and

the therapy delivery circuit is configured to cancel a delayed ATP therapy in response to the control circuit determining the slowing event.

6. The medical device of claim 1 , wherein the therapy delivery circuit is configured to adjust the high voltage capacitor charge by dumping a portion of a residual charge stored on the high voltage capacitor through a non-therapeutic load.

7. The medical device of claim 1 , wherein the therapy delivery circuit is configured to adjust the high voltage capacitor charge to the pacing voltage amplitude by charging the high voltage capacitor up to the pacing voltage amplitude.

8. The medical device of claim 1 , wherein the control circuit is further configured to:

determine from the cardiac electrical signal that the tachyarrhythmia has accelerated during the ATP therapy delay period; and

the therapy delivery circuit is configured to:

terminate adjusting the high voltage capacitor to the pacing voltage amplitude in response to the control circuit determining that the tachyarrhythmia has accelerated;

charge the high voltage capacitor to the shock voltage amplitude in response to the tachyarrhythmia being accelerated; and

deliver a cardioversion/defibrillation shock pulse having the shock voltage amplitude.

9. The medical device of claim 1 , wherein the control circuit is further configured to:

compare a charge of the high voltage capacitor to the pacing voltage amplitude in response to detecting the tachyarrhythmia;

determine that a difference between the charge of the high voltage capacitor and the pacing voltage amplitude is greater than a difference threshold; and

cancel a delayed ATP therapy in response to the difference being greater than the difference threshold.

10. The medical device of claim 9 , wherein the therapy delivery circuit is configured to charge the high voltage capacitor to the shock voltage amplitude in response to the ATP therapy being cancelled.

11. A method comprising:

receiving a cardiac electrical signal;

detecting a tachyarrhythmia from the cardiac electrical signal;

starting an anti-tachycardia pacing (ATP) therapy delay period in response to detecting the tachyarrhythmia; and

adjusting a charge of a high voltage capacitor to a pacing voltage amplitude during the ATP therapy delay period, wherein the high voltage capacitor is chargeable to a shock voltage amplitude for delivering a cardioversion/defibrillation shock pulse and the pacing voltage amplitude is less than the shock voltage amplitude.

12. The method of claim 11 , further comprising:

determining the charge of the high voltage capacitor during the ATP therapy delay period;

determining when the charge of the high voltage capacitor is within a tolerance of the pacing voltage amplitude; and

delivering a delayed ATP therapy after the ATP therapy delay period in response to the high voltage capacitor being within the tolerance of the pacing voltage amplitude during the ATP therapy delay period.

13. The method of claim 12 , further comprising:

cancelling the delayed ATP therapy in response to the high voltage capacitor not being within the tolerance of the pacing voltage amplitude during the ATP therapy delay period; and

charging the high voltage capacitor to the shock voltage amplitude in response to the ATP therapy being cancelled.

14. The method of claim 11 , further comprising:

determining that ATP delivery criteria are not satisfied based on the cardiac electrical signal received during the ATP therapy delay period; and

cancelling a delayed ATP therapy in response to the ATP delivery criteria not being satisfied.

15. The method of claim 11 , further comprising:

determining that a cardiac event sensed by the sensing circuit from the cardiac electrical signal during the ATP therapy delay period is a slowing event; and

cancelling a delayed ATP therapy in response to the control circuit determining the slowing event.

16. The method of claim 11 , further comprising adjusting the high voltage capacitor charge by dumping a portion of a residual charge stored on the high voltage capacitor through a non-therapeutic load.

17. The method of claim 11 , further comprising adjusting the high voltage capacitor charge to the pacing voltage amplitude by charging the high voltage capacitor up to the pacing voltage amplitude.

18. The method of claim 11 , further comprising:

determining from the cardiac electrical signal that the tachyarrhythmia has accelerated during the ATP therapy delay period;

terminating adjusting the high voltage capacitor to the pacing voltage amplitude in response to determining that the tachyarrhythmia has accelerated;

charging the high voltage capacitor to the shock voltage amplitude in response to the tachyarrhythmia being accelerated; and

delivering a cardioversion/defibrillation shock pulse having the shock voltage amplitude.

19. The method of claim 11 , further comprising:

comparing a charge of the high voltage capacitor to the pacing voltage amplitude in response to detecting the tachyarrhythmia;

determining that a difference between the charge of the high voltage capacitor and the pacing voltage amplitude is greater than a difference threshold; and

cancelling a delayed ATP therapy in response to the difference being greater than the difference threshold.

20. The method of claim 19 , further comprising charging the high voltage capacitor to the shock voltage amplitude in response to the delayed ATP therapy being cancelled.

21. A non-transitory, computer-readable medium storing a set of instructions which, when executed by a control circuit of a medical device, cause the medical device to:

receive a cardiac electrical signal;

detect a tachyarrhythmia from the cardiac electrical signal;

start an anti-tachycardia pacing (ATP) therapy delay period in response to detecting the tachyarrhythmia; and

adjust a charge of a high voltage capacitor to a pacing voltage amplitude during the ATP therapy delay period, wherein the high voltage capacitor is chargeable to a shock voltage amplitude for delivering a cardioversion/defibrillation shock pulse, and the pacing voltage amplitude is less than the shock voltage amplitude.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: ZHANG, XUSHENG; GRINBERG, YANINA; SOLHEIM, PAUL R.; JACKSON, TROY E.; EBELING, TIMOTHY A.; NIKOLSKI, VLADIMIR P.
To: MEDTRONIC, INC. (CVG)
Reel/Frame 052866/0713 →
Continuity (2)
Continuation 15677204 · Aug 15, 2017
Related Publication 20200298003A1 · Sep 24, 2020